ArticleClinicoEconomics and outcomes research : CEOR2022

Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds.

Thomas Wilke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.